Trillium Therapeutics to Present at Investor Conferences in April
TORONTO, April 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company’s programs and progress at the following upcoming conferences:
H.C. Wainwright Global Life Sciences Conference Presenter: Dr. Niclas Stiernholm, Chief Executive OfficerDate and Time: April 9, 2019 at 3:10 p.m. BSTLocation: Grosvenor House, London
18th Annual Needham Healthcare ConferencePresenter: Dr. Bob Uger, Chief Scientific Officer Date and Time: April 10, 2019 at 12:00 p.m. ETLocation: Westin Grand Central Hotel, New York City
A live audio webcast of the H.C. Wainwright Global Life Sciences Conference presentation will be available under the investor relations section of Trillium’s website at www.trilliumtherapeutics.com.
About Trillium Therapeutics
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “do not eat” signal that cancer cells frequently use to evade the immune system. Trillium also has a preclinical STING program and a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.
For more information, visit: www.trilliumtherapeutics.com
Contact and Investor Relations:James ParsonsChief Financial OfficerTrillium Therapeutics Inc. 416-595-0627 x232 email@example.com
Media Relations:Jessica Tieszen Canale Communications for Trillium Therapeutics 619-849-5385 firstname.lastname@example.org